Rezistenca ndaj antibiotikëve veçanërisht nga bakteret gram-negative pothuajse ka krijuar një situatë të ngjashme me krizën. Antibiotiku i ri Zosurabalpin (RG6006) tregon premtime. Është gjetur të jetë efektiv kundër baktereve GRAM-negative CRAB rezistente ndaj ilaçeve në studimet para-klinike.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of antibiotikët to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of antibiotik rezistenca.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available antibiotikët. There is an urgent need for an effective antibiotik against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective antibiotik. A progress towards this goal has been reported.
Scientists have identified a novel class of antibiotikët namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpin (RG6006) është një antibiotik candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-klinik trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame antibiotik-resistance mechanism of CARB suggesting Zosurabalpin ka potencial.
Hence, human klinik trials have been initiated to check for safety and efficacy Zosurabalpin në trajtimin e infeksioneve invazive të shkaktuara nga GAFORRJA.
***
Referencat:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel antibiotik class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Hawser S., et al 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Klinik Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
